We are thrilled to introduce Release Tx's Scientific Advisory Board (SAB), which brings together leading experts in leukodystrophies, neurosurgery, gene and cell therapies and neursociences:
Caroline Sevin, MD, PhD — Paediatric Neurologist and Head of the Reference Centre for Leukodystrophies
Timothée de Saint-Denis, MD, PhD — Paediatric Neurosurgeon, Armand-Trousseau Hospital, Paris
Bernard Schneider, PhD — Head of the Bertarelli Platform for Gene Therapy, EPFL Lausanne
Aurélien Lathuilière, MD, PhD — Neurologist, HUG Memory Centre, Geneva
Our collaboration with the Paris Brain Institute’s Innovation Unit of Gene and Cell Therapy (GENOV) has achieved a historic milestone this year: the successful brain implantation of ARSA-producing human myoblasts using our Encapsulated Cell Technology in a ground=breaking non-human primate study. Early observations point to transformative possibilities, with data revealing our technology's reassuring safety profile and meaningful therapeutic potential.
In last' weeks inaugural SAB meeting, Dr. Françoise Piguet (GENOV) and Dr. Julien Grogg (Release Tx) presented compelling evidence of our platform's potential to provide a new treatment option for metachromatic leukodystrophy (MLD). This devastating genetic disorder, which typically claims young lives before the age of five, drives our determined search for new treatments.
As we close this milestone year, we're poised for significant advances in 2025. Our mission remains clear: to develop an effective treatment for MLD and bring new hope to affected families.
Thank you to our dedicated team, partners, and SAB members who share our commitment to this crucial work.
Warm holiday wishes to all, and here's to advancing science and medicine in 2025!
The Release Tx Team
Comments